Breaking Finance News

Abbott Laboratories (NYSE:ABT) has been upgraded to Strong-Buy in a report by BidaskClub today.

BidaskClub has upgraded Abbott Laboratories (NYSE:ABT) to Strong-Buy in a statement released on Saturday June 17, 2017.

Previously on 6/14/2017, Zacks Investment Research released a statement for Abbott Laboratories (NYSE:ABT) bumped up the target price from $0.00 to $53.00. At the time, this indicated a possible upside of 0.11%.

Displaying a price of $48.21, Abbott Laboratories (NYSE:ABT) traded 1.62% higher on the day. With the last stock price close up 11.10% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. The company has recorded a 50-day moving average of $50.15 and a 200-day moving average of $47.04. 4,911,513 shares of the stock were exchanged, down from an average trading volume of 5,273,110

Performance Chart

Abbott Laboratories (NYSE:ABT)

Abbott Laboratories has a 52 week low of $37.38 and a one year high of $52.60 with a PE ratio of 73.20 Abbott Laboratories’s market capitalization is currently $0.

Also covering Abbott Laboratories's price target, a total of 15 brokerages have released a ratings update on ABT. The one year target is $46.73 with six brokers rating the stock a strong buy, 8 brokers rating the stock a buy, 6 firms rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 equity analysts rating the company a sell.

More About Abbott Laboratories (NYSE:ABT)

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.